Loading...

Correvio Pharma

DB:72R
Snowflake Description

High growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
72R
DB
CA$142M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Correvio Pharma has significant price volatility in the past 3 months.
72R Share Price and Events
7 Day Returns
-5.4%
DB:72R
-0.9%
DE Pharmaceuticals
1.5%
DE Market
1 Year Returns
27.2%
DB:72R
-21.6%
DE Pharmaceuticals
-6.2%
DE Market
72R Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Correvio Pharma (72R) -5.4% -14% -11.4% 27.2% -36.8% -56.2%
DE Pharmaceuticals -0.9% 0.2% -0.9% -21.6% -25.8% 6.4%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • 72R outperformed the Pharmaceuticals industry which returned -21.6% over the past year.
  • 72R outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
72R
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Correvio Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Correvio Pharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Correvio Pharma.

DB:72R Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:72R
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.733 (1 + (1- 26.5%) (39.15%))
0.962
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.96
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.962 * 5.96%)
5.96%

Discounted Cash Flow Calculation for DB:72R using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Correvio Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:72R DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.96%)
2019 -17.83 Analyst x1 -16.83
2020 2.85 Analyst x1 2.53
2021 19.41 Analyst x1 16.31
2022 34.37 Analyst x1 27.26
2023 45.98 Analyst x1 34.42
2024 55.32 Est @ 20.31% 39.08
2025 63.23 Est @ 14.29% 42.15
2026 69.59 Est @ 10.07% 43.79
2027 74.55 Est @ 7.12% 44.27
2028 78.31 Est @ 5.05% 43.89
Present value of next 10 years cash flows $276.88
DB:72R DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $78.31 × (1 + 0.23%) ÷ (5.96% – 0.23%)
$1,368.80
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,368.80 ÷ (1 + 5.96%)10
$767.06
DB:72R Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $276.88 + $767.06
$1,043.94
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,043.94 / 39.20
$40.76
DB:72R Discount to Share Price
Calculation Result
Exchange Rate USD/CAD
(Reporting currency to currency of TSX:CORV)
1.342
Value per Share
(CAD)
= Value per Share in USD x Exchange Rate (USD/CAD)
= $26.63 x 1.342
CA$35.74
Non-primary Listing Adjustment Factor 1 share in DB:72R represents 0.65331x of TSX:CORV
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.65331x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (CAD) x Listing Adjustment Factor
= CA$ 35.74 x 0.65331
€23.35
Value per share (EUR) From above. €23.35
Current discount Discount to share price of €2.37
= -1 x (€2.37 - €23.35) / €23.35
89.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Correvio Pharma is available for.
Intrinsic value
>50%
Share price is €2.37 vs Future cash flow value of €23.35
Current Discount Checks
For Correvio Pharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Correvio Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Correvio Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Correvio Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Correvio Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:72R PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.47
TSX:CORV Share Price ** TSX (2019-04-23) in CAD CA$3.62
TSX:CORV Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.745 $2.7
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 26.82x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Correvio Pharma.

DB:72R PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:CORV Share Price ÷ EPS (both in USD)

= 2.7 ÷ -0.47

-5.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Correvio Pharma is loss making, we can't compare its value to the DE Pharmaceuticals industry average.
  • Correvio Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Correvio Pharma's expected growth come at a high price?
Raw Data
DB:72R PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.72x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
58.5%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.78x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Correvio Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Correvio Pharma's assets?
Raw Data
DB:72R PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.19
TSX:CORV Share Price * TSX (2019-04-23) in CAD CA$3.62
TSX:CORV Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.745 $2.7
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.39x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:72R PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:CORV Share Price ÷ Book Value per Share (both in USD)

= 2.7 ÷ 0.19

14.14x

* Primary Listing of Correvio Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Correvio Pharma is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Correvio Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Correvio Pharma has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Correvio Pharma expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
58.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Correvio Pharma expected to grow at an attractive rate?
  • Correvio Pharma's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Correvio Pharma's earnings growth is expected to exceed the Germany market average.
  • Correvio Pharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:72R Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:72R Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 58.5%
DB:72R Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 29.1%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 19.7%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:72R Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:72R Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 138 33 38 3
2022-12-31 115 20 24 3
2021-12-31 88 -2 2 3
2020-12-31 61 35 -14 5
2019-12-31 36 -22 -27 5
DB:72R Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 29 -26 -17
2018-09-30 27 -26 -18
2018-06-30 26 -24 -18
2018-03-31 25 -26 -32
2017-12-31 24 -25 -30
2017-09-30 24 -24 -27
2017-06-30 23 -23 -26
2017-03-31 23 -17 -25
2016-12-31 25 -16 -20
2016-09-30 23 -17 -21
2016-06-30 23 -15 -22
2016-03-31 23 -18 -22

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Correvio Pharma's earnings are expected to grow significantly at over 20% yearly.
  • Correvio Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:72R Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Correvio Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:72R Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.72 0.84 0.61 3.00
2022-12-31 0.45 0.59 0.37 3.00
2021-12-31 0.03 0.17 -0.17 3.00
2020-12-31 -0.36 -0.22 -0.60 5.00
2019-12-31 -0.72 -0.68 -0.76 3.00
DB:72R Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.47
2018-09-30 -0.53
2018-06-30 -0.52
2018-03-31 -0.94
2017-12-31 -0.90
2017-09-30 -0.83
2017-06-30 -0.82
2017-03-31 -0.88
2016-12-31 -0.78
2016-09-30 -0.96
2016-06-30 -1.10
2016-03-31 -1.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Correvio Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Correvio Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Correvio Pharma has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Correvio Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Correvio Pharma's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Correvio Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Correvio Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Correvio Pharma's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Correvio Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Correvio Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:72R Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 28.67 -16.58 40.78
2018-09-30 26.76 -18.48 43.14
2018-06-30 25.78 -18.00 42.43
2018-03-31 25.35 -31.94 39.38
2017-12-31 24.01 -29.81 36.69
2017-09-30 23.99 -27.06 35.38
2017-06-30 23.21 -25.72 34.06
2017-03-31 23.37 -24.72 32.47
2016-12-31 25.26 -19.62 30.51
2016-09-30 22.96 -21.44 29.68 0.06
2016-06-30 22.68 -21.96 29.74 0.08
2016-03-31 22.50 -21.81 30.15 3.16
2015-12-31 20.91 -24.46 30.20 3.22
2015-09-30 23.17 -23.54 31.08 3.26
2015-06-30 26.02 -22.10 31.71 3.48
2015-03-31 27.95 -18.98 32.14 0.45
2014-12-31 30.04 -18.23 33.81 0.64
2014-09-30 26.93 -18.97 31.95 0.58
2014-06-30 19.60 -18.22 28.04 0.38
2014-03-31 12.04 -16.75 22.24 0.35
2013-12-31 4.51 4.77 16.45 0.48
2013-09-30 0.73 19.75 11.37 0.82
2013-06-30 0.31 9.95 9.91 6.42
2013-03-31 0.42 7.05 9.12 6.39
2012-12-31 0.79 -18.32 9.46 6.02
2012-09-30 1.11 -31.96 9.35 5.63
2012-06-30 1.32 -25.70 9.62

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Correvio Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Correvio Pharma has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Correvio Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Correvio Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Correvio Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Correvio Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Correvio Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Correvio Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Correvio Pharma's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Correvio Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Correvio Pharma Company Filings, last reported 3 months ago.

DB:72R Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 6.91 41.52 15.60
2018-09-30 10.14 40.72 16.75
2018-06-30 14.76 39.95 21.87
2018-03-31 9.09 39.21 13.60
2017-12-31 16.19 40.00 22.08
2017-09-30 23.30 39.01 27.18
2017-06-30 28.86 28.45 28.38
2017-03-31 28.17 19.44 19.37
2016-12-31 34.02 19.39 26.76
2016-09-30 40.04 19.34 31.53
2016-06-30 12.78 19.31 12.88
2016-03-31 19.48 8.66 11.54
2015-12-31 19.94 9.60 17.66
2015-09-30 26.82 11.00 24.75
2015-06-30 10.22 12.00 7.62
2015-03-31 14.06 12.00 9.19
2014-12-31 17.14 12.00 12.71
2014-09-30 23.45 12.00 17.58
2014-06-30 28.15 0.00 9.35
2014-03-31 32.25 0.00 13.24
2013-12-31 22.64 0.00 10.98
2013-09-30 20.19 0.00 17.28
2013-06-30 23.69 0.00 19.71
2013-03-31 26.35 0.00 25.75
2012-12-31 7.86 32.50 41.00
2012-09-30 -0.31 50.00 53.62
2012-06-30 12.94 50.00 60.68
  • Correvio Pharma's level of debt (600.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 600.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Correvio Pharma has less than a year of cash runway based on current free cash flow.
  • Correvio Pharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.1% each year.
X
Financial health checks
We assess Correvio Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Correvio Pharma has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Correvio Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Correvio Pharma dividends.
If you bought €2,000 of Correvio Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Correvio Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Correvio Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:72R Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:72R Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Correvio Pharma has not reported any payouts.
  • Unable to verify if Correvio Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Correvio Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Correvio Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Correvio Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Correvio Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Correvio Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Correvio Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mark H. Corrigan
COMPENSATION $238,895
AGE 60
TENURE AS CEO 0.1 years
CEO Bio

Dr. Mark H. N. Corrigan, M.D., is Lead Independent Director of Blackthorn Therapeutics, Inc. since November 5, 2018. Dr. Corrigan has been an Chairman of Novelion Therapeutics Inc. since March 2019 and was its Executive Chairman since July 03, 2018 until Marc 2019. Dr. Corrigan served as the Chief Executive Officer and President of Zalicus Inc. from January 2010 to June 2014. Dr. Corrigan is a seasoned life sciences executive. Dr. Corrigan joined the specialty pharmaceutical company Sepracor Inc. in 2003. He served as an Executive Vice President of Research & Development of Sunovion Pharmaceuticals Inc. from April 21, 2003 to December 2009. He has over 20 years of experience in treating psychiatric and central nervous system disorders. He has been involved in the development of several drugs including Estorraä for the treatment of insomnia, Xopenexâ for the treatment of Parkinson's disease, Delavirdine for AIDS, Cycloprovera for birth control, Xalantan for glaucoma, Camptosar for colorectal cancer and Reboxetine for depression. Dr. Corrigan served as Group Vice President of Global Clinical Research and Experimental Medicine at Pharmacia Corp. from 1998 to 2003 with responsibility for clinical research, biostatistical/data management and global procurement for compounds in Phases I-IIIB. Dr. Corrigan spent seven years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. He joined Upjohn in 1993 and served in several senior management positions in clinical research and development. He spent 10 years with Pharmacia & Upjohn and served as Group Vice President of global clinical research and experimental medicine. He was the Chairman of the Board at Blackthorn Therapeutics, Inc. until November 5, 2018. He serves as Chairman of Scientific Advisory Board at Oxeia Biopharmaceuticals, Inc. He served as the Chairman of EPIRUS Biopharmaceuticals, Inc. since July 15, 2014 until July 25, 2016 and its Director since December 2009 until July 25, 2016. He has been a Director of Synereca Pharmaceuticals, Inc. since May 20, 2015. He has been a Director of Pamlico Biopharma, Inc., since August 2015, Correvio Pharma Corp. since June 22, 2015 and Novelion Therapeutics Inc. since March 31, 2017. He is Director of Tremeau Pharmaceuticals. He serves as CEO at Correvio Pharma Corp. since March 14, 2019. He has been Director of Nabriva Therapeutics plc since June 23, 2017. He served as a Director of Zalicus Inc. since December 2009. Dr. Corrigan served as a Director of Avanir Pharmaceuticals, Inc. from March 19, 2014 to January 13, 2015. He served as a Director at CoLucid Pharmaceuticals, Inc. since October 2015 until March 1, 2017. He served as a Director of Neuromed Pharmaceuticals, Ltd. He served as a Director of Cubist Pharmaceuticals Inc. from June 2008 to January 2015. He is an Adjunct Clinical Professor of Psychiatry. He was a principal investigator for several novel antipsychotics. He is a board certified in Psychiatry and Neurology. He is a Distinguished Fellow of the American Psychiatric Association (APA). Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and received specialty training in Psychiatry at Cornell University and Maine Medical Center.

CEO Compensation
  • Mark H.'s compensation has increased whilst company is loss making.
  • Mark H.'s remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Correvio Pharma management team in years:

1.9
Average Tenure
57
Average Age
  • The average tenure for the Correvio Pharma management team is less than 2 years, this suggests a new team.
Management Team

Mark H. Corrigan

TITLE
CEO & Director
COMPENSATION
$239K
AGE
60
TENURE
0.1 yrs

Justin Renz

TITLE
CFO & President
COMPENSATION
$1M
AGE
46
TENURE
0.3 yrs

Sheila Grant

TITLE
Chief Operating Officer
COMPENSATION
$637K
TENURE
6.1 yrs

David McMasters

TITLE
General Counsel
COMPENSATION
$738K
AGE
59
TENURE
6.4 yrs

Bill Hunter

TITLE
Executive Officer & Director
COMPENSATION
$2M
AGE
55
TENURE
0.1 yrs

Hugues Sachot

TITLE
Chief Commercial Officer
COMPENSATION
$708K
TENURE
2.5 yrs

David Dean

TITLE
Chief Business Development Officer
TENURE
1.9 yrs
Board of Directors Tenure

Average tenure and age of the Correvio Pharma board of directors in years:

3.8
Average Tenure
60
Average Age
  • The tenure for the Correvio Pharma board of directors is about average.
Board of Directors

Jim O'Shea

TITLE
Chairman
COMPENSATION
$2M
AGE
68
TENURE
3.8 yrs

Mark H. Corrigan

TITLE
CEO & Director
COMPENSATION
$239K
AGE
60
TENURE
3.8 yrs

Bill Hunter

TITLE
Executive Officer & Director
COMPENSATION
$2M
AGE
55
TENURE
11.8 yrs

Richard Glickman

TITLE
Director
COMPENSATION
$139K
AGE
60
TENURE
12.3 yrs

Arthur Willms

TITLE
Director
COMPENSATION
$148K
TENURE
3.8 yrs

Robert Meyer

TITLE
Director
COMPENSATION
$126K
TENURE
3.6 yrs

Vanda De Cian

TITLE
Director
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
16. Jan 19 Buy Justin Renz Individual 15. Jan 19 15. Jan 19 20,000 €1.93 €38,614
21. Aug 18 Sell David McMasters Individual 16. Aug 18 16. Aug 18 -10,000 €4.37 €-43,709
28. Jun 18 Sell David McMasters Individual 27. Jun 18 27. Jun 18 -5,603 €3.30 €-18,463
26. Jun 18 Sell David McMasters Individual 21. Jun 18 21. Jun 18 -4,000 €3.21 €-12,827
X
Management checks
We assess Correvio Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Correvio Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.

Details
Name: Correvio Pharma Corp.
72R
Exchange: DB
Founded: 2018
CA$94,624,716
39,203,943
Website: http://www.correvio.com
Address: Correvio Pharma Corp.
1441 Creekside Drive,
6th Floor,
Vancouver,
British Columbia, V6J 4S7,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX CORV Common Shares The Toronto Stock Exchange CA CAD 26. Jan 1990
NasdaqCM CORV Common Shares Nasdaq Capital Market US USD 26. Jan 1990
DB 72R Common Shares Deutsche Boerse AG DE EUR 26. Jan 1990
Number of employees
Current staff
Staff numbers
138
Correvio Pharma employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 21:46
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/03/25
Last earnings filing: 2019/03/13
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.